“If I have ever made any valuable discoveries, it has been owing more to patient attention, than to any other talent.”

Novel biologics
for treatment of
fibrosis & cancer

Novel biologics
for treatment of
fibrosis & cancer

ABOUT

We design and develop biologics

Forbius (Formation Biologics) is a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. Forbius was founded in 2011 as a management-led spin out from YM BioSciences, prior to YM's acquisition by Gilead.

Forbius’ medicines are designed to radically transform patients’ lives. Our strength is utilizing our knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways.

 

Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer

Our current focus is the development of agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. For both of these pathways, there is a significant body of evidence validating their role as drivers of multiple life-threatening conditions. However, in the case of the EGFR pathway, the majority of patients do not benefit from currently marketed EGFR inhibitors. In the case of the TGF-beta pathway, not a single agent targeting this pathway has yet been approved. By using multiple complimentary platform technologies, Forbius’ team overcame barriers that prevented development of highly-active therapeutics targeting these pathways.

Technology

Our Toolbox

By utilizing multiple complementary platform technologies, Forbius engineers proprietary, fit-for-purpose biotherapeutics positioned to
become the new standard of care. Our strength is designing highly active inhibitors of validated pathways that have a differentiated
mechanism of action.

  • Traps
  • mAbs
  • ADCs
  • In Silico

Receptor ectodomain-based traps

Forbius uses receptor ectodomain-based trap technology to design selective and potent traps that neutralize ligands that are over-expressed in disease. We have a unique approach to designing traps that results in superior potency compared to traditional trap engineering approaches.

Monoclonal antibodies

Forbius uses novel immunization and screening approaches to enable identification of unique monoclonal antibodies (mAbs) with desired activities.

Antibody-drug conjugates

Forbius utilizes antibody-drug conjugate (ADC) technology to enhance the activity of antibodies targeting internalizing cell surface proteins that are over-expressed in disease.

In Silico

Forbius utilizes cutting-edge in silico protein modelling platforms to accelerate and optimize design of its biotherapeutics.

Pipeline

Our Products

Fibrosis
Cancer

AVID 100 anti-EGFR ADC

Discovery

Preclinical

Clinical phase

1
2
3

Marketed

SCCHN

NSCLC

TNBC

More about AVID100

AVID100 is a highly potent anti-EGFR antibody-drug conjugate. This agent successfully completed Phase 1 testing and is now undergoing Phase 2a clinical trials in EGFR-overexpressing tumors.

AVID200 TGF-ß inhibitor

Discovery

Preclinical

Clinical phase

1
2
3

Marketed

Immune Oncology

Systemic Sclerosis

Myelofibrosis

More about AVID200

AVID200 is designed to be a highly potent and isoform-selective TGF-β inhibitor. This agent is unique because it selectively neutralizes TGF-β1 and -β3 with pM potency, while at the same time being minimally active against TGF-β 2. Inhibiting the TGF-β1 and -β3 isoforms is advantageous because overexpression of these isoforms is closely associated with the progression of fibrosis and cancer. Conversely, blockade of TGF-β2 is undesirable because of the potential impact on normal cardiac function and dissemination of metastasis. We therefore believe that AVID200 is ideally positioned to be an effective and well-tolerated therapeutic in a variety of clinical settings. AVID200 is undergoing development for the treatment of fibrotic diseases and immune oncology.

AVID300 TGF-ß inhibitor

Discovery

Preclinical

Clinical phase

1
2
3

Marketed

Fibrosis, subcutaneous formulation

AVID400 Undisclosed

Discovery

Preclinical

Clinical phase

1
2
3

Marketed

Undisclosed

Team

Led by Innovators

  • Management
  • Board of Directors
  • Advisors & Collaborators

Business Development

For partnering and business development enquiries, please contact us at: bd@forbius.com

Research Collaborations

If you are a clinician or researcher interested in collaborating with us, please contact us at: info@forbius.com

Partners

Our Partners

Careers

Working at Forbius

Forbius is a rapidly growing, science-driven company. We are pleased to hear from individuals with a track-record of achievement who are interested in joining our team. Click here to learn more about our corporate culture and open positions.

Join the Team

Austin

106 E. 6th Street, Suite 200
Austin, Texas 78701

Get Directions

Montréal

750 Boul. Saint-Laurent, Suite 101
Montréal, Quebec H2Y 2Z4

Get Directions

General inquiry

Please email us at: info@forbius.com